EGFR and neoplasm: In patients with left-sided RAS wild-type early tumor shrinkage–positive metastatic CRC, there were no statistically significant differences in overall survival, PFS, or postprogression survival between anti-EGFR–based therapy and bevacizumab-based therapy (overall survival, HR = 0.92 [95% CI = 0.80 to 1.05]; PFS, HR = 0.94 [95% CI = 0.83 to 1.08]; postprogression survival, HR = 0.86 [95% CI = 0.73 to 1.02]).